Lipoatrophy associated with glatiramer acetate injections for the treatment of multiple sclerosis.
Hwang
L
L
Department of Dermatology, Baylor College of Medicine Houston, Texas 77030, USA.
Orengo
I
I
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000009:adverse effects*; D000328:Adult; D005260:Female; D000068717:Glatiramer Acetate; D006801:Humans; D007279:Injections, Subcutaneous; D008060:Lipodystrophy / Q000139:chemically induced* / Q000473:pathology; D009103:Multiple Sclerosis / Q000188:drug therapy*; D010455:Peptides / Q000008:administration & dosage / Q000009:adverse effects*; D012008:Recurrence; D013601:T-Lymphocytes / Q000276:immunology
D000276:Adjuvants, Immunologic; D010455:Peptides; D000068717:Glatiramer Acetate